Rituximab-related viral infections in lymphoma patients.
Leuk Lymphoma
; 48(7): 1307-12, 2007 Jul.
Article
em En
| MEDLINE
| ID: mdl-17613758
ABSTRACT
Recently, a human/mouse chimeric monoclonal antibody, rituximab, has been successfully used to treat cases of B-cell non-Hodgkin's lymphoma and some autoimmune diseases. However, several viral infections related to rituximab have been reported in the literature, but were not well characterized. To further investigate this topic, relevant English language studies were identified through Medline. There were 64 previously reported cases of serious viral infection after rituximab treatment. The median age of the cases was 61 years (range 21 - 79). The median time period from the start of rituximab treatment to viral infection diagnosis was 5.0 months (range 1 - 20). The most frequently experienced viral infections were hepatitis B virus (HBV) (39.1%, n = 25), cytomegalovirus infection (CMV) (23.4%, n = 15), varicella-zoster virus (VZV) (9.4%, n = 6), and others (28.1%, n = 18). Of the patients with HBV infections, 13 (52.0%) died due to hepatic failure. Among the 39 cases that had viral infections other than HBV, 13 died due to these specific infections. In this study, about 50% of the rituximab-related HBV infections resulted in death, whereas this was the case in only 33% of the cases with other infections. Close monitoring for viral infection, particularly HBV and CMV, in patients treated with rituximab should be recommended.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Viroses
/
Linfoma
/
Anticorpos Monoclonais
Tipo de estudo:
Systematic_reviews
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Leuk Lymphoma
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Turquia